Guillain-Barré syndrome epidemiology and demographics: Difference between revisions

	Guillain-Barré syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Guillain-Barré syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Guillain-Barré syndrome epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Guillain-Barré syndrome epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Guillain-Barré syndrome epidemiology and demographics
CDC on Guillain-Barré syndrome epidemiology and demographics
Guillain-Barré syndrome epidemiology and demographics in the news
Blogs on Guillain-Barré syndrome epidemiology and demographics
Directions to Hospitals Treating Guillain-Barré syndrome
Risk calculators and risk factors for Guillain-Barré syndrome epidemiology and demographics

VisualWikitext

Revision as of 15:35, 14 December 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. The incidence is approximately 1.2 - 3 / 100,000 persons per year across the world. It is commoner in males compared to female and has two peaks (15-35 years and 50-75 years). Incidence is similar across different races.

Epidemiology and Demographics

Incidence

Incidence vary from 0.4 to 4.0 cases per population of 100 000.

Case mortality rate

in previous studies, Guillain-Barre syndrome mortality rate was 2.58%.

Age

It can happen in any age group but it’s more common in late adolescence.
The reason behind this is that immune suppressor mechanisms will decrease with age.

Races

It was demonstrated in one study that the incidence rate for whites were 0.44 and for blacks were 0.28 per 100,000, but it seems that despite all of these, the incidence is similar across different races.

Gender

It is more common among males compared to females. Male to female ratio 1.5:1.

References

Template:WH Template:WS

@@ Line 8: / Line 8: @@
 ==Epidemiology and Demographics==
 ===Incidence===
-* It is the commonest cause of acute, flaccid paralysis in USA.
+* Incidence vary from 0.4 to 4.0 cases per population of 100 000.
-* Incidence- 1.2 - 3 / 100,000 persons  <ref name="pmid1741839">{{cite journal |author=Day N |title=AIDS and insurer discretion |journal=[[Ohio Medicine : Journal of the Ohio State Medical Association]] |volume=87 |issue=5 |pages=226 |year=1991 |month=May |pmid=1741839 |doi= |url= |accessdate=2012-02-17}}</ref><ref name="pmid1187127">{{cite journal |author=Romhányi I |title=[Letter: The concept of "caucasian race"] |language=Hungarian |journal=[[Orvosi Hetilap]] |volume=116 |issue=41 |pages=2449 |year=1975 |month=October |pmid=1187127 |doi= |url= |accessdate=2012-02-17}}</ref>
-* It has been reported all over the world.
-* The incidence is around 1.5 - 3 / 100,000 persons
-* The antecedence of [[Campylobacter jejuni]] is commoner in Japan and other Asian countries. Whereas, in American continents and European nations an antecedence of [[cytomegalovirus]] is common.
 === Case mortality rate ===
+* in previous studies, Guillain-Barre syndrome mortality rate was 2.58%.
 ===Age===
-* Incidence increases with age.
+* It can happen in any age group but it’s more common in late adolescence.
-* Bimodal distribution - First peak during 15 - 35 yrs and second during old age <ref name="pmid9203708">{{cite journal |author=Prevots DR, Sutter RW |title=Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance |journal=[[The Journal of Infectious Diseases]] |volume=175 Suppl 1 |issue= |pages=S151–5 |year=1997 |month=February |pmid=9203708 |doi= |url=http://www.jid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=9203708 |accessdate=2012-02-17}}</ref>.
+* The reason behind this is that immune suppressor mechanisms will decrease with age.
-* New-borns and infants have the least risks of development of GBS
 ===Races===
-* Incidence is similar across different races.
+* It was demonstrated in one study that the incidence rate for whites were 0.44 and for blacks were 0.28 per 100,000, but it seems that despite all of these, the incidence is similar across different races.
 ===Gender===
-* It occurs more commonly in males compared to females. Male to female ratio 1.5:1
+* It is more common among males compared to females. Male to female ratio 1.5:1.
-* The incidence has been found to increase post-partum and decreases during pregnancy <ref name="pmid8817501">{{cite journal |author=Jiang GX, de Pedro-Cuesta J, Strigård K, Olsson T, Link H |title=Pregnancy and Guillain-Barré syndrome: a nationwide register cohort study |journal=[[Neuroepidemiology]] |volume=15 |issue=4 |pages=192–200 |year=1996 |pmid=8817501 |doi= |url= |accessdate=2012-02-19}}</ref>
 ==References==